I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Breast Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. To participate in the I-SPY 2.2 clinical trial, a person's breast tumor must be at Stage II or III (the tumor has grown beyond the breast and may involve nearby lymph nodes or tissues). Patients with rare types of breast cancer like metaplastic and inflammatory carcinomas and patients with extensive Ductal Carcinoma In Situ (DCIS) are eligible if their cancer has spread to the lymph nodes
    2. Clinically node-negative disease: breast cancer has not spread to nearby lymph nodes that can be felt or seen on imaging tests but still have measurable disease in the breast after a biopsy (diameter of the cancer is at least 25 millimeters)
    3. Clinically node-positive disease: the cancer in the breast is visible using medical imaging (the size of the cancer is at least 20mm)

You may not be eligible for this study if the following are true:

    1. Uncontrolled or severe heart, brain, lung, pancreas, kidney, or liver problems
    2. Known personal or family history of Long QT syndrome (Long QT syndrome is a heart condition that can be inherited and can cause dangerous heart rhythms)
    3. A history of having an organ transplant, active pneumonitis (lung inflammation), myelodysplastic syndrome (a condition affecting the bone marrow), or leukemia (a type of blood cancer)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.